Oct 21 (Reuters) – Actinogen Medical Ltd: * NARROW GUIDANCE FOR TOPLINE RESULTS FOR XANAMIA PHASE 2B/3 ALZHEIMER'S DISEASE CLINICAL TRIAL TO MID-NOV THIS YEAR Further company coverage:
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
A possible SpaceX-Tesla merger? Here's what people are saying
Oct 21 (Reuters) - Elon Musk said on Tuesday that a merger of his two…
Meet the 193-year-old tortoise that could hold the key to longer life
London (dpa) - In what University of Cambridge scientists hope could lead to a "blueprint" for…
Foden hat trick helps Man City to 5-1 win over AEK Athens
VIDEO SHOWS: POST-MATCH PRESS CONFERENCE WITH MANCHESTER CITY MANAGER ENZO MARESCA COMPLETE SHOTLIST AND SCRIPT…
